Updated analysis showed longer progression-free and overall survival for patients with advanced renal cell carcinoma
Change in subcutaneous fat after initiation of immune checkpoint inhibitors may distinguish which patients will and will not respond to therapy.
In a study, partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
Investigators conclude that pN1 RCC could be stratified into pN1 and pN2, with pN2 conferring a poor prognosis comparable to that of non-metastatic stage IV pN0 disease.
Findings may inform treatment decisions after nephrectomy with positive surgical margins.
Cabozantinib can produce responses in patients with advanced clear cell RCC whose disease progressed on first-line checkpoint inhibitor-based therapy, a phase 2 study suggests.
Nephron-sparing management is one strategy to reduce risks, according to investigators.
Management of metastatic renal cell carcinoma should be highly individualized, according to investigators.
Postoperative opioid prescriptions are associated with delayed recovery, perioperative complications, and opioid misuse, investigators noted.
Certain patients with resected renal cell carcinoma may benefit from adjuvant treatment with immune checkpoint inhibitors, a meta-analysis suggests.